Clinical Trials
Search documents
Could digital twins – virtual replicas of humans or organs – accelerate medical research? 🏥
Google DeepMind· 2025-07-03 11:17
Digital Twins in Healthcare - Digital twins are a significant topic, especially for healthcare applications [1] - The concept involves creating digital replicas for individual healthcare purposes, with varied interpretations [1] Pharmaceutical Industry Applications - The pharma industry explores digital twins to enhance clinical trials [2] - Virtual cohorts could potentially reduce the number of participants needed in clinical trials while maintaining knowledge about drug safety and efficacy [2][3] - This approach simulates human systems (e g, organs) to minimize reliance on human subjects in trials [2]
2 Beaten-Down Stocks With Massive Upside Potential
The Motley Fool· 2025-07-03 11:00
Group 1: CRISPR Therapeutics - CRISPR Therapeutics has developed Casgevy, the first gene-editing medicine approved using the CRISPR technique, but the stock has been on a downward trend since 2021 due to clinical progress, complexity of therapy administration, and unprofitability [3][4] - The company is targeting challenging areas such as type 1 diabetes and hard-to-treat cancers, with expected data readouts for ongoing clinical trials as early as this year, which could positively impact stock performance [5] - Casgevy has significant financial implications, with a treatment cost of $2.2 million in the U.S. and an estimated 60,000 patients in target geographies, indicating blockbuster potential [9] Group 2: Viking Therapeutics - Viking Therapeutics gained attention after strong phase 2 results for VK2735, an investigational weight management therapy, but has seen stock performance decline as investors took profits [10] - The anti-obesity therapy market is rapidly growing, and Viking's VK2735 has shown promising mid-stage data, with an oral formulation currently in Phase 2 studies [11] - Viking Therapeutics has a robust pipeline, including VK2809 for metabolic dysfunction-associated steatohepatitis entering phase 3 studies and VK0214 for X-linked adrenoleukodystrophy, which has received orphan drug designation [12][13]
